155 related articles for article (PubMed ID: 37643052)
21. Vogt-Koyanagi-Harada disease-like uveitis after drug therapy including BRAF/MEK inhibitors in melanoma patients with HLA-DRB1*04.
Amagai R; Fujimura T; Yamazaki E; Takahashi M; Tamabuchi E; Kambayashi Y; Hashimoto A; Hashimoto K; Asano Y
J Dermatol; 2024 Jun; 51(6):854-857. PubMed ID: 38111371
[TBL] [Abstract][Full Text] [Related]
22. VOGT-KOYANAGI-HARADA-LIKE UVEITIS FOLLOWED BY MELANOMA-ASSOCIATED RETINOPATHY WITH FOCAL CHORIORETINAL ATROPHY AND CHOROIDAL NEOVASCULARIZATION IN A PATIENT WITH METASTATIC CUTANEOUS MELANOMA.
Ng CC; Alsberge JB; Qian Y; Freund KB; Cunningham ET
Retin Cases Brief Rep; 2023 Jan; 17(1):18-22. PubMed ID: 33394953
[TBL] [Abstract][Full Text] [Related]
23. Development of Acute Vogt-Koyanagi-Harada-like Syndrome during the Treatment Course with Vemurafenib for Metastatic Melanoma.
Apivatthakakul A; Kunavisarut P; Rothova A; Pathanapitoon K
Ocul Immunol Inflamm; 2020 Apr; 28(3):505-508. PubMed ID: 31161956
[No Abstract] [Full Text] [Related]
24. Unilateral Ocular Manifestations of Vogt-Koyanagi-Harada Disease.
Tsui E; Bottini A; Ghadiali Q; Balaratnasingam C; Barbazetto I
Ocul Immunol Inflamm; 2018; 26(8):1297-1300. PubMed ID: 29020488
[TBL] [Abstract][Full Text] [Related]
25. Vogt-Koyanagi-Harada-like Syndrome Complicating Pembrolizumab Treatment for Metastatic Melanoma.
Bricout M; Petre A; Amini-Adle M; Bezza W; Seve P; Kodjikian L; Dalle S; Thomas L
J Immunother; 2017; 40(2):77-82. PubMed ID: 28166182
[TBL] [Abstract][Full Text] [Related]
26. Outcome of Nivolumab-Induced Vogt-Koyanagi-Harada Disease-Like Uveitis in a Patient Managed without Intravenous Methylprednisolone Therapy.
Nagai R; Yamamoto A; Yoshida A; Mikawa A
Case Rep Ophthalmol Med; 2023; 2023():9565205. PubMed ID: 36818144
[TBL] [Abstract][Full Text] [Related]
27. Vogt-Koyanagi-Harada-like syndrome in the setting of combined anti-PD1/anti-CTLA4 therapy.
Godse R; Mcgettigan S; Schuchter LM; Ellebrecht CT; Chu EY
Clin Exp Dermatol; 2021 Aug; 46(6):1111-1112. PubMed ID: 33846999
[No Abstract] [Full Text] [Related]
28. Vogt-Koyanagi-Harada disease-like posterior uveitis in the course of nivolumab (anti-PD-1 antibody), interposed by vemurafenib (BRAF inhibitor), for metastatic cutaneous malignant melanoma.
Matsuo T; Yamasaki O
Clin Case Rep; 2017 May; 5(5):694-700. PubMed ID: 28469878
[TBL] [Abstract][Full Text] [Related]
29. Clinical characteristics of Vogt-Koyanagi-Harada syndrome in Chinese patients.
Yang P; Ren Y; Li B; Fang W; Meng Q; Kijlstra A
Ophthalmology; 2007 Mar; 114(3):606-14. PubMed ID: 17123618
[TBL] [Abstract][Full Text] [Related]
30. Comparison of Clinical Features and Visual Outcome between Sympathetic Ophthalmia and Vogt-Koyanagi-Harada Disease in Chinese Patients.
Yang P; Liu S; Zhong Z; Du L; Ye Z; Zhou W; Kijlstra A
Ophthalmology; 2019 Sep; 126(9):1297-1305. PubMed ID: 30959067
[TBL] [Abstract][Full Text] [Related]
31. [Bilateral Nivolumab-associated Vogt-Koyanagi-Harada-like Uveitis in a Patient with Metastatic Renal Cell Carcinoma].
Czichos C; Wawrzynów B; Chamalis C; von Jagow B
Klin Monbl Augenheilkd; 2021 Jun; 238(6):711-714. PubMed ID: 33395707
[No Abstract] [Full Text] [Related]
32. Induction of Vogt-Koyanagi-Harada Disease by Interferon-Alpha and Ribavirin Treatment in Patients with Hepatitis C: A Case Report and Review of the Literature.
Duan J; Wang Y; Liu D; Ma J
Ocul Immunol Inflamm; 2019; 27(2):229-234. PubMed ID: 29023176
[TBL] [Abstract][Full Text] [Related]
33. Vogt-Koyanagi-Harada Disease Exacerbation Associated with COVID-19 Vaccine.
De Domingo B; López M; Lopez-Valladares M; Ortegon-Aguilar E; Sopeña-Perez-Argüelles B; Gonzalez F
Cells; 2022 Mar; 11(6):. PubMed ID: 35326462
[TBL] [Abstract][Full Text] [Related]
34. Treatment of Ipilimumab-Induced Vogt-Koyanagi-Harada Syndrome With Oral Dexamethasone.
Witmer MT
Ophthalmic Surg Lasers Imaging Retina; 2017 Nov; 48(11):928-931. PubMed ID: 29121363
[TBL] [Abstract][Full Text] [Related]
35. Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors results from the WHO's pharmacovigilance database.
Anquetil C; Salem JE; Lebrun-Vignes B; Touhami S; Desbois AC; Maalouf G; Domont F; Allenbach Y; Cacoub P; Bodaghi B; Saadoun D
J Autoimmun; 2020 Jul; 111():102454. PubMed ID: 32303423
[TBL] [Abstract][Full Text] [Related]
36. Incomplete Vogt-Koyanagi-Harada disease following treatment with encorafenib and binimetinib for metastatic melanoma.
Diamantopoulos PT; Stoungioti S; Anastasopoulou A; Papaxoinis G; Gogas H
Melanoma Res; 2018 Dec; 28(6):648-651. PubMed ID: 30169430
[TBL] [Abstract][Full Text] [Related]
37. Ocular Adverse Events following Use of Immune Checkpoint Inhibitors for Metastatic Malignancies.
Noble CW; Gangaputra SS; Thompson IA; Yuan A; Apolo AB; Lee JM; Papaliodis GN; Kodati S; Bishop R; Magone MT; Sobrin L; Sen HN
Ocul Immunol Inflamm; 2020 Aug; 28(6):854-859. PubMed ID: 31013173
[TBL] [Abstract][Full Text] [Related]
38. Development of Vogt-Koyanagi-Harada disease-like uveitis during treatment by anti-programmed death-1 antibody: a case report.
Wang JN; Zhang Y; Huang CY; Li K; Yu XB
BMC Ophthalmol; 2024 Jun; 24(1):240. PubMed ID: 38849786
[TBL] [Abstract][Full Text] [Related]
39. Unilateral Posterior Uveitis in a Patient Receiving Nivolumab for Malignant Melanoma.
Giannakis P; Malik M; Rashid S; Vrizidou E
Cureus; 2023 Aug; 15(8):e43311. PubMed ID: 37700996
[TBL] [Abstract][Full Text] [Related]
40. Vogt-Koyanagi-Harada disease.
O'Keefe GA; Rao NA
Surv Ophthalmol; 2017; 62(1):1-25. PubMed ID: 27241814
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]